Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;81(1):29-41.
doi: 10.4046/trd.2017.0120.

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Chi Young Jung  1 , Scott J Antonia  2
Affiliations
Review

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Chi Young Jung et al. Tuberc Respir Dis (Seoul). 2018 Jan.

Abstract

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only 10%-20%. Obviously, new therapeutic options are required for patients with advanced NSCLC and unmet medical needs. Cancer immunotherapy is an evolving treatment modality that uses a patient's own immune systems to fight cancer. Theoretically, cancer immunotherapy can result in long-term cancer remission and may not cause the same side effects as chemotherapy and radiation. Immuno-oncology has become an important focus of basic research as well as clinical trials for the treatment of NSCLC. Immune checkpoint inhibitors are the most promising approach for cancer immunotherapy and they have become the standard of care for patients with advanced NSCLC. This review summarizes basic tumor immunology and the relevant clinical data on immunotherapeutic approaches, especially immune checkpoint inhibitors in NSCLC.

Keywords: Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported

Figures

Figure 1
Figure 1. The three phases of the cancer immunoediting process: elimination, equilibrium, and escape. DC: dendritic cell; γδ: γδ T cell; IDO: indoleamine 2,3-dioxygenase; IFN-γ: interferon γ; IL: interleukin; M1: M1 macrophage; M2: M2 macrophage; MDSC: myeloid-derived suppressor cell; NK: natural killer cell; NKT: natural killer T cell; PD-L1: programmed death ligand 1; TGF-β: transforming growth factor β; Treg: regulatory T cell. Modified from Schreiber et al. Science 2011;331:1565-70, with permission of The American Association for the Advancement of Science.
Figure 2
Figure 2. The cancer-immunity cycle. APC: antigen presenting cell; MHC: major histocompatibility complex; TCR: T cell receptors.
Figure 3
Figure 3. The immune system activation and checkpoint inhibitors. APC: antigen presenting cell; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1; TCR: T cell receptors. Modified from Pardoll. Nat Rev Cancer 2012;12:252-64, with permission of Springer Nature.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2013 [Internet] Goyang: National Cancer Information Center; 2016. [cited 2016 Jun 20]. Available from: http://www.cancer.go.kr/
    1. Korean Statistical Information Service. Statistics Korea [Internet] Daejeon: Statistics Korea; 2016. [cited 2016 Jun 20]. Available from: http://kosis.kr/
    1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–719. - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: non-small cell lung cancer. Version 9. 2017 [Internet] Fort Washington: National Comprehensive Cancer Network; 2017. [cited 2017 Sep 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.